David M. Chao Sells 7,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider David M. Chao sold 7,000 shares of the firm’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $17.17, for a total value of $120,190.00. Following the completion of the transaction, the insider now directly owns 225,007 shares of the company’s stock, valued at approximately $3,863,370.19. This trade represents a 3.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Centessa Pharmaceuticals Stock Up 1.6 %

Shares of NASDAQ CNTA traded up $0.26 during trading hours on Wednesday, hitting $16.77. The company had a trading volume of 627,614 shares, compared to its average volume of 518,437. The stock has a market capitalization of $2.21 billion, a P/E ratio of -10.96 and a beta of 1.54. Centessa Pharmaceuticals plc has a 1-year low of $7.75 and a 1-year high of $19.09. The firm’s 50 day moving average is $16.45 and its 200-day moving average is $16.36. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating on the stock. Guggenheim restated a “buy” rating on shares of Centessa Pharmaceuticals in a report on Monday, February 10th. Finally, Morgan Stanley reissued an “overweight” rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $26.00.

Institutional Trading of Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. acquired a new position in shares of Centessa Pharmaceuticals during the 4th quarter worth approximately $31,000. GAMMA Investing LLC grew its position in Centessa Pharmaceuticals by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after buying an additional 865 shares in the last quarter. Barclays PLC increased its stake in Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company’s stock worth $89,000 after acquiring an additional 4,952 shares during the period. BNP Paribas Financial Markets acquired a new position in Centessa Pharmaceuticals in the 4th quarter valued at $162,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of Centessa Pharmaceuticals during the 4th quarter valued at $171,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.